ArticleEJHaem2026
Association of Frailty With Transfusions, Hospitalizations, and Survival in Patients With Myelodysplastic Syndrome Initiating Hypomethylating Agents.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Prognostic scoring systems in MDS lack functional status measures. We sought to evaluate the influence of frailty on overall survival and care utilization in a national cohort. We conducted a retrospective study in the US Veterans Affairs Healthcare System of patients with MDS initiated on hypomethylating agents (HMAs) from 2004 to 2023. Frailty was measured using the Veterans Affairs-Frailty Index (VA-FI). Methods: For primary analyses, we evaluated the association between severity of frailty and overall survival via Kaplan-Meier analysis, followed by Cox proportional hazard regression models. Multivariable Poisson regression was used to evaluate transfusion incidence and unplanned hospitalizations. We identified 2285 veterans with MDS who initiated HMA treatment. The median age was 73.2 years. In addition, 34.0%, 30.6%, and 35.4% of veterans were classified as non-frail, mildly frail, and moderate-to-severely frail, respectively. Results: Moderate-to-severely frail veterans had a 49% higher hazard of death (aHR, 1.49; 95% CI, 1.34-1.67), as well as a higher incidence of transfusions (aIRR, 1.61; 95% CI, 1.45-1.80) and hospitalizations (aIRR, 1.58; 95% CI, 1.51-1.64). Conclusion: Increasing frailty was associated with higher rates of death, hospitalizations, and transfusions. Further research is needed to characterize how MDS-related contributors to frailty and non-oncologic aging-related factors mediate the increased risk of inferior outcomes in this population. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.